Skip to main content
image of man and woman inside PLUVICTO

Men who received PLUVICTO plus standard therapy*:

Lived longer, with a median of 15 months vs 11 months with standard therapy alone

Saw their tumors shrink or disappear, 30% vs 2% with standard therapy alone

*Standard therapy was chosen by a doctor from among existing approved treatments and did not include chemotherapy, immunotherapy, systemic isotopes like radium-223 (223Ra), or drugs still being studied.

PLUVICTO can help you be you for longer, giving you the chance for more everyday victories

If you have advanced prostate cancer, you know every day matters.  PLUVICTO could give you more time for what's important to you and your loved ones. That's a victory.

See How PLUVICTO May Help
 

After hormone therapy and chemotherapy, ask about PLUVICTO.
It's not chemotherapy. It's the FIRST and ONLY PSMA-targeted radioligand therapy.

Find out if PLUVICTO could be the next step for you or a loved one. Follow these links to explore why:

If you or a loved one has started on PLUVICTO, here's what you need to know:

Watch the video to see what everyday victories could mean for you.

Interested in receiving information about PLUVICTO?

PLUVICTO® Pulse provides educational support and materials for those considering and starting on treatment.

mCRPC, metastatic castration-resistant prostate cancer; PSMA+, prostate-specific membrane antigen positive.